TuisBEAM • NASDAQ
add
Beam Therapeutics Inc
Vorige sluiting
$24,02
Dagwisseling
$23,66 - $26,15
Jaarwisseling
$16,95 - $49,50
Markkapitalisasie
1,96 mjd USD
Gemiddelde volume
1,54 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2023info | J/J-verandering |
|---|---|---|
Inkomste | 316,19 m | 1 478,04% |
Bedryfskoste | 43,26 m | 90,72% |
Netto inkomste | 142,80 m | 472,36% |
Netto winsgrens | 45,16 | 123,60% |
Wins per aandeel | 1,73 | 420,37% |
EBITDA | 138,22 m | 262,53% |
Effektiewe belastingkoers | 0,95% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2023info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,19 mjd | 10,36% |
Totale bates | 1,46 mjd | 8,79% |
Totale aanspreeklikheid | 478,38 m | -21,35% |
Totale ekwiteit | 981,33 m | — |
Uitstaande aandele | 78,73 m | — |
Prys om te bespreek | 1,93 | — |
Opbrengs op bates | 24,15% | — |
Opbrengs op kapitaal | 31,52% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2023info | J/J-verandering |
|---|---|---|
Netto inkomste | 142,80 m | 472,36% |
Kontant van bedrywe | 135,07 m | 295,22% |
Kontant van beleggings | 98,10 m | -13,52% |
Kontant van finansiering | 33,71 m | 5,31% |
Netto kontantverandering | 266,88 m | 249,97% |
Beskikbare kontantvloei | 95,32 m | 278,82% |
Meer oor
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. Wikipedia
HUB
Gestig
2017
Webwerf
Werknemers
436
